Skip to main content

Ovid Therapeutics Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

OVID$2.850.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)For The Three Months EndedJune 30, 2025For The Three Months EndedJune 30, 2024For The Six Months EndedJune 30, 2025For The Six Months EndedJune 30, 2024
Revenue:
License and other revenue$6,272$169$6,402$317
Total revenue6,2721696,402317
Operating expenses:
Research and development6,46512,58213,12322,984
General and administrative4,8808,10410,90215,267
Total operating expenses11,34520,68624,02538,251
Loss from operations(5,073)(20,517)(17,623)(37,934)
Other income (expense), net38929,0382,70434,760
(Loss) income before provision for income taxes(4,684)8,521(14,919)(3,174)
Provision for income taxes————
Net (loss) income$(4,684)$8,521$(14,919)$(3,174)
Net (loss) income per share of Series A preferred stock, basic$(64.73)$118.07$(206.27)$(44.04)
Net (loss) income per share of Series A preferred stock, diluted$(64.73)$117.61$(206.27)$(44.04)
Weighted-average Series A preferred stock shares outstanding, basic and diluted1,2501,2501,2501,250
Net (loss) income per share of common stock, basic$(0.06)$0.12$(0.21)$(0.04)
Net (loss) income per share of common stock, diluted$(0.06)$0.12$(0.21)$(0.04)
Weighted-average common stock shares outstanding, basic71,109,51470,916,47171,077,74770,816,585
Weighted-average common stock shares outstanding, diluted71,109,51471,200,79871,077,74770,816,585
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.